

ASX ANNOUNCEMENT

14 October 2024

## Completion of Retail Entitlement Offer

**Sunnyvale, California; 14 October 2024: EBR Systems, Inc.** (ASX: “**EBR**”, “**EBR Systems**” or the “**Company**”) developer of the world’s only wireless cardiac pacing device for heart failure, is today pleased to announce the completion of the retail component (**Retail Entitlement Offer**) of its fully underwritten 1 for 20 pro-rata accelerated non-renounceable entitlement offer of new CHESS Depository Interests (**CDIs**) at an issue price of A\$0.82 per CDI (**New CDI**) to raise approximately A\$50.0 million (**Entitlement Offer**).

The Retail Entitlement Offer represents the final stage of EBR’s Entitlement Offer. The institutional component of the Entitlement Offer completed on 20 September 2024.

The Retail Entitlement Offer closed at 5:00pm (Sydney time) on Wednesday, 9 October 2024 with valid applications received for 3,736,403 New CDIs (including applications under the top-up facility for approximately 1,162,287 New CDIs) raising approximately A\$3.06 million. Applications under the top-up facility which exceeded the 100% cap (totalling 61,535 New CDIs in aggregate) will be scaled back to the cap.

The entitlements of ineligible retail securityholders and entitlements not taken up by eligible retail securityholders represent approximately 1,339,330 New CDIs and will be placed in accordance with the terms of the underwriting agreement between EBR, Bell Potter Securities Limited (ACN 006 390 772) (**Bell Potter**), Morgans Corporate Limited (ACN 010 539 607) and E&P Capital Pty Limited (ACN 137 980 520). The Retail Entitlement Offer is fully underwritten by Bell Potter.

The New CDIs will be issued on Wednesday, 16 October and are expected to commence trading on ASX on Thursday, 17 October 2024. New CDIs will rank equally with existing CDIs in all respects from the date of issue.

***This announcement has been authorised for release by John McCutcheon, President and CEO.***

**ENDS**

**For more information, please contact:**

**Company**

Gary Doherty  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

**Investors**

Joel Seah  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

## **About EBR Systems (ASX: EBR)**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

## **EBR Systems' WiSE Technology**

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## **Foreign Ownership Restriction**

EBR's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.